Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Godley
Lucy A
LA
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL 60637, USA. lgodley@medicine.bsd.uchicago.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002872:Chromosome Deletion; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D018450:Disease Progression; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012307:Risk Factors; D014178:Translocation, Genetic; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl